Malignant tumor
Conditions
Interventions
Alpha beta T cell therapy CTL (Cyototoxic T Lymphocytes) therapy Gammma delta T cell therapy NK (Natural Killer) cell therapy Dendritic cell therapy
Sponsors
KOUSHIKAI,Non-profitmedicalcorporation
01.Seta Clinic Tokyo 02.LSI Sapporo Clinic 03.Kyoaikai Hospital 04.Sano Hospital 05.Toyoaki Clinic 06.Miki Hospital 07.Tozai Clinic Sendai 08.Omachi Medical and Surgical Clinic 09.Benibana Medical Clinic 10.Kaneko Clinic 11.Kikkoman General Hospital 12.Clinic Kashiwanoha 13.TouTou 14.Shinbashi Ekimae Medical Clinic 15.Azabu Clinic 16.TKC Tokyo clinic 17.Kanamecho Hospital 18.Kanamecho Home Care Clinic 19.Kawaguchi Gastroenterology Clinic 20.HAYAMA HEART CENTER
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Diagnostic imaging or Pathological diagnosis of malignant tumor. 2)Informed consent has been obtained.
Exclusion criteria
Exclusion criteria: 1) HIV Ab positive. 2) T cell- or NK cell-originated leukemia and/or lymphoma.(LAK therapy) 3)Patients who have previously treated allogenic transplantation. 4) Responsible doctors judged the patient inappropriate for the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The defined safety* and efficacy** set is analyzed and evaluated annually according to the Act on the Safety of Regenerative Medicine. *severity, date, frequency, duration, incidence rate and attribution of adverse events **clinical and antitumor effect evaluation, disease-specific overall survival and others (progression-free survival, relapse-free survival, efficacy rate, disease control rate and tumor marker levels) | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response | — |
Countries
Japan
Contacts
Public ContactEri Oguma
KOUSHIKAI,Non-profitmedicalcorporation Center for Clinical Trials and Research
Outcome results
None listed